Topic: amyloid burden

Regulatory approvals of Aducanumab in the U.S. and Lecanemab (U.S and Japan) for the treatment of Alzheimer’s disease (AD) have launched the worldwide marketing campaign for these antibodies as one of the first drugs that not only alleviate the symptoms but also slow AD progression. Another potent anti-amyloid antibody, Donanemab, may gain approval in the near future, as it is reported to reduce amyloid burden and slow AD progression. However, the risk/benefit profile of these drugs remains uncertain, and there is no obvious scientific basis for choosing between different antibodies. Here, we

Alzheimer’s disease (AD) is a neurodegenerative disorder with complex pathological manifestations and is the leading cause of cognitive decline and dementia in elderly individuals. A major goal in AD research is to identify new therapeutic pathways by studying the molecular and cellular changes in the disease, either downstream or upstream of the pathological hallmarks. In this study, we present a comprehensive investigation of cellular heterogeneity from temporal cortex region of 40 individuals, comprising healthy donors and individuals with differing tau and amyloid burden. Using single-nucl